CTOs on the Move

Curemark

www.curemark.com

 
Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark`s pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson`s disease.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.curemark.com
  • 800 Westchester Avenue
    Rye Brook, NY USA 10573
  • Phone: 914.824.9700

Executives

Name Title Contact Details

Similar Companies

Caribou Biosciences

Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types. Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing. Members of the Caribou herd open their minds to new ideas and welcome diverse perspectives. We proudly assert that teams do their best work when their members are personally engaged, their ideas are taken seriously, their contributions are recognized, and their needs are met.

DynamiCure

DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and autoimmune disease. We are driven by science and passionate about advancing patient care, translating pioneering new insights on immuno-normalization into a pipeline of innovative candidates with first-in-class and best-in-class potential. Since our founding in 2019, we have identified and obtained exclusive global rights to several novel targets and are rapidly advancing into the clinic both monoclonal and bispecific therapeutic antibody candidates.

Chinook Therapeutics

Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $100 billion in annual costs.

Achieve Life Science

Achieve is a specialty pharmaceutical company committed to advancing cytisine as a widely available treatment option to help people battling nicotine addiction.

StageBio

StageBio serves preclinical histology, pathology and specimen archiving clients in the biopharmaceutical, medical device and contract research industries.